Sphera Funds Management Ltd. Mirati Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $6.25 Million - $8.39 Million	-47,309 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$144.0 - $179.73 $2.52 Million - $3.15 Million	17,530 Added 58.87%	47,309 $7.64 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $521,963 - $773,909	-3,221 Reduced 9.76%	29,779 $6.54 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $4.42 Million - $6.52 Million	-39,000 Reduced 54.17%	33,000 $5.48 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $5.18 Million - $8.67 Million	72,000 New	72,000 $8.22 Million

Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $3.61 Million - $5.36 Million	-112,908 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $4.64 Million - $6.18 Million	98,573 Added 687.64%	112,908 $5.32 Million
Q2 2018 Aug 13, 2018	BUY	$26.05 - $52.4 $373,426 - $751,154	14,335 New	14,335 $707,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.